Fig. 3
From: Tumor endothelial ELTD1 as a predictive marker for treatment of renal cancer patients with sunitinib
a and b: Progression free survival (3A) and overall survival (3B) and expression of ELTD1 in sunitinib treated patients. Patients treated for metastatic renal cell cancer with sunitinib in the first or second line setting (n = 77) comparing ELTD1 low versus ELTD1 high. c and d: Progression free survival (3C) and overall survival (3D) in sorafenib treated and expression of ELTD1. Patients treated for metastatic renal cell cancer with sorafenib in the first or second line setting (n = 53) comparing ELTD1 low versus ELTD1 high